Publications and Presentations

HFB200301

HFB301001

HFB200603

HFB200902

HFB101110

HFB100204

American Association for Cancer Research | Presentation | April 12, 2021

Discovery and characterization of a novel anti-human CXCR5 antibody for the treatment of B cell lymphomas

DIS® Platform

Drug Discovery Today | Publication | October 17, 2023

Drug Intelligence Science (DIS®): Pioneering a high-resolution translational platform to enhance the probability of success for drug discovery and development Drug Intelligence Science (DIS®): Pioneering a high-resolution translational platform to enhance the probability of success for drug discovery and development

American Association for Cancer Research | Poster | April 08, 2022

Discovery of predictive biomarkers of response to T cell-targeting biologics using ex vivo single-cell profiling coupled with TCR clonotype characterization Discovery of predictive biomarkers of response to T cell-targeting biologics using ex vivo single-cell profiling coupled with TCR clonotype characterization

Science Advances | Publication | June 11, 2021

High-throughput functional screening for next-generation cancer immunotherapy using droplet-based microfluidics

American Association for Cancer Research | Presentation | September 17, 2020

HiFiBiO Therapeutics Presents Novel Approach to Patient Stratification Demonstrating DIS™ Single-Cell Platform at 2020 AACR Tumor Heterogeneity Conference

Nature Biotechnology | Publication | March 30, 2020

High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics

Nature Genetics | Publication | May 31, 2019

High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer

Nature Biotechnology | Publication | September 11, 2017

Single-cell deep phenotyping of IgG-secreting cells for high-resolution immune monitoring Single-cell deep phenotyping of IgG-secreting cells for high-resolution immune monitoring

HiFiBio, Paris | Poster | November 13, 2016

Antibody Discovery by Deep Mining of Immune Repertoires: A demonstration of the HiFiBiO CelliGO™ Platform versatility and robustness with Tetanus Toxoid antigen as a case study Antibody Discovery by Deep Mining of Immune Repertoires: A demonstration of the HiFiBiO CelliGO™ Platform versatility and robustness with Tetanus Toxoid antigen as a case study

Other Programs

Biotech2050 | Podcast | June 14, 2023 | 30m 57s

CEO Liang Schweizer speaks with Rahul Chaturvedi on the Biotech2050 Podcast about her journey from scientist to first-time CEO and how HiFiBiO is improving the success rate of immunotherapies by leveraging unprecedented single-cell level insights into patient heterogeneity.

Life Science Success Podcast | Podcast | January 5, 2023 | 28m 18s

CEO Liang Schweizer spoke with Don Davis on the Life Science Success Podcast about her professional journey and how HiFiBiO is using DIS® to accelerate the delivery of precision immunotherapies to patients.

Dealmakers Show | Podcast | September 9, 2022 | 35m

CEO Liang Schweizer appeared on the Dealmakers Show by Alejandro Cremades to share the advantages of starting global, managing remote working in drug discovery, building a strong global culture, and how she raised over $180 million in funding.

Talking Biotech Podcast | Podcast | August 20, 2022 | 52m 03s

CEO Liang Schweizer shared her thoughts and experience with Kevin Folta on the Talking Biotech podcast on how HiFiBiO is using single-cells and microfluidics to identify new antibodies, as well as what could guide application of the most effective treatments.

Lioness Magazine Interview | Interview | March 11, 2021 | 35m 23s

CEO Liang Schweizer shared with Lioness Magazine how HiFiBiO combines biological expertise with single-cell profiling technologies to advance antibody drugs. She also highlighted the importance of community service and mentorship to her successes.

Genialis Podcast | Podcast | February 26, 2021 | 51m 07s

CEO Liang Schweizer spoke with Rafael Rosengarten from Genialis about Drug Intelligence Science (DIS®) that combines data intelligence with single-cell science to achieve optimal outcomes for all stages of drug discovery and development.

PharmaBoardRoom Article | Article | February 17, 2021

CEO Liang Schweizer introduced HiFiBiO Therapeutics, the main advantages of the company’s unique single-cell technology platform, its open innovation approach, experience with capital markets, and advice for other biotech leaders.

BioBoss Podcast | Podcast | September 29, 2019 | 48m

CEO Liang Schweizer interviewed with John Simboli on the BioBoss podcast to share her perspectives on biotech leadership and highlight the uniqueness of HiFiBiO’s single-cell driven Drug Intelligence Science (DIS®) approach and highly diverse teams.